retatrutide lawsuit Significantly Reduces Visceral Fat in Clinical Trials Novo Nordisk Seeks Injunction Against

After the initial 36 weeks, participants lost 21.1% of their body weight After the following 52 weeks, the tirzepatide group lost another 6.7% of their body weight, while the placebo group regained 14.8% Through the 88-week study, the tirzepatide group lost 26% of their body weight Tirzepatide had a similar safety profile in SURMOUNT-3 and SURMOUNT-4 as its previous trials, most commonly citing mild-moderate gastrointestinal issues

B.ChenV

An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

Treatment starts with injections three times per week for three weeks, then continues weekly

His skin was a mess

Switching to tirzepatide gives you a second mechanism to try